|
HY-P99376-1mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
|
HY-P99376-10mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
|
HY-P99376-5mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
|
HY-108831A-1mg
|
MedChemexpress LLC
|
Natalizumab (Solution) [CAS 189261-10-7]
|
|
|
|
|
HY-108831A-10mg
|
MedChemexpress LLC
|
Natalizumab (Solution) [CAS 189261-10-7]
|
|
|
|
|
HY-108831A-25mg
|
MedChemexpress LLC
|
Natalizumab (Solution) [CAS 189261-10-7]
|
|
|
|
|
HY-108831A-5mg
|
MedChemexpress LLC
|
Natalizumab (Solution) [CAS 189261-10-7]
|
|
|
|
|
HY-108831-10mg
|
MedChemexpress LLC
|
Natalizumab [CAS 189261-10-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-108831-25mg
|
MedChemexpress LLC
|
Natalizumab [CAS 189261-10-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-108831-5mg
|
MedChemexpress LLC
|
Natalizumab [CAS 189261-10-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99206-1mg
|
MedChemexpress LLC
|
Naxitamab [CAS 1879925-92-4]
|
|
Cancer-programmed cell death
|
|
|
HY-P99206-10mg
|
MedChemexpress LLC
|
Naxitamab [CAS 1879925-92-4]
|
|
Cancer-programmed cell death
|
|
|
HY-P99206-5mg
|
MedChemexpress LLC
|
Naxitamab [CAS 1879925-92-4]
|
|
Cancer-programmed cell death
|
|
|
HY-P99379-1mg
|
MedChemexpress LLC
|
Nidanilimab [CAS 2171061-85-9]
|
|
Cancer-programmed cell death
|
|
|
HY-P99379-10mg
|
MedChemexpress LLC
|
Nidanilimab [CAS 2171061-85-9]
|
|
Cancer-programmed cell death
|
|
|
HY-P99379-5mg
|
MedChemexpress LLC
|
Nidanilimab [CAS 2171061-85-9]
|
|
Cancer-programmed cell death
|
|
|
HY-P9968-1mg
|
MedChemexpress LLC
|
Nimotuzumab [CAS 780758-10-3]
|
|
Cancer-Kinase/protease
|
|
|
HY-P9968-5mg
|
MedChemexpress LLC
|
Nimotuzumab [CAS 780758-10-3]
|
|
Cancer-Kinase/protease
|
|
|
HY-W539893-100mg
|
MedChemexpress LLC
|
NODAGA-tris(t-Bu ester) [CAS 1190101-34-8]
|
|
Cancer-programmed cell death
|
|
|
HY-P9932-1mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P9932-10mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P9932-5mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P9910-1mg
|
MedChemexpress LLC
|
Obinutuzumab [CAS 949142-50-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P9910-10mg
|
MedChemexpress LLC
|
Obinutuzumab [CAS 949142-50-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P9910-5mg
|
MedChemexpress LLC
|
Obinutuzumab [CAS 949142-50-1]
|
|
Cancer-programmed cell death
|
|
